Novartis (Brazil) Buy Hold or Sell Recommendation
| N1VS34 Stock | BRL 50.47 0.69 1.39% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Novartis AG is 'Strong Buy'. Macroaxis provides Novartis buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Novartis positions. The advice algorithm takes into account all of Novartis' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Novartis' buy or sell advice are summarized below:
Real Value 59.32 | Hype Value 50.47 | Market Value 50.47 | Naive Value 50.87 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Novartis AG given historical horizon and risk tolerance towards Novartis. When Macroaxis issues a 'buy' or 'sell' recommendation for Novartis AG, the advice is generated through an automated system that utilizes algorithms and statistical models.
Novartis |
Execute Novartis Buy or Sell Advice
The Novartis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Novartis AG. Macroaxis does not own or have any residual interests in Novartis AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Novartis' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Novartis Trading Alerts and Improvement Suggestions
| Novartis AG generated a negative expected return over the last 90 days | |
| The company has accumulated 22.9 B in total debt with debt to equity ratio (D/E) of 0.7, which is about average as compared to similar companies. Novartis AG has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novartis until it has trouble settling it off, either with new capital or with free cash flow. So, Novartis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novartis AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novartis to invest in growth at high rates of return. When we think about Novartis' use of debt, we should always consider it together with cash and equity. |
Novartis Returns Distribution Density
The distribution of Novartis' historical returns is an attempt to chart the uncertainty of Novartis' future price movements. The chart of the probability distribution of Novartis daily returns describes the distribution of returns around its average expected value. We use Novartis AG price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Novartis returns is essential to provide solid investment advice for Novartis.
| Mean Return | -0.1 | Value At Risk | -1.9 | Potential Upside | 2.37 | Standard Deviation | 1.21 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Novartis historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Novartis Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Novartis or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Novartis' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Novartis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.11 | |
β | Beta against NYSE Composite | -0.01 | |
σ | Overall volatility | 1.19 | |
Ir | Information ratio | -0.16 |
Novartis Volatility Alert
Novartis AG exhibits very low volatility with skewness of -0.49 and kurtosis of 2.59. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Novartis' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Novartis' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Novartis Fundamentals Vs Peers
Comparing Novartis' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Novartis' direct or indirect competition across all of the common fundamentals between Novartis and the related equities. This way, we can detect undervalued stocks with similar characteristics as Novartis or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Novartis' fundamental indicators could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Novartis to competition |
| Fundamentals | Novartis | Peer Average |
| Return On Equity | 0.11 | -0.31 |
| Return On Asset | 0.0645 | -0.14 |
| Profit Margin | 0.13 % | (1.27) % |
| Operating Margin | 0.25 % | (5.51) % |
| Current Valuation | 1.1 T | 16.62 B |
| Shares Outstanding | 2.12 B | 571.82 M |
| Price To Earning | 15.16 X | 28.72 X |
| Price To Book | 0.33 X | 9.51 X |
| Price To Sales | 19.86 X | 11.42 X |
| Revenue | 52.88 B | 9.43 B |
| Gross Profit | 36.74 B | 27.38 B |
| EBITDA | 33.06 B | 3.9 B |
| Net Income | 24.02 B | 570.98 M |
| Cash And Equivalents | 10.69 B | 2.7 B |
| Cash Per Share | 4.70 X | 5.01 X |
| Total Debt | 22.9 B | 5.32 B |
| Debt To Equity | 0.70 % | 48.70 % |
| Current Ratio | 0.91 X | 2.16 X |
| Book Value Per Share | 28.00 X | 1.93 K |
| Cash Flow From Operations | 15.07 B | 971.22 M |
| Earnings Per Share | 16.38 X | 3.12 X |
| Price To Earnings To Growth | 0.58 X | 4.89 X |
| Number Of Employees | 102 K | 18.84 K |
| Beta | 0.47 | -0.15 |
| Market Capitalization | 970.05 B | 19.03 B |
| Total Asset | 131.79 B | 29.47 B |
| Z Score | 25.2 | 8.72 |
| Annual Yield | 0.04 % | |
| Net Asset | 131.79 B | |
| Last Dividend Paid | 3.46 |
Novartis Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Novartis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Novartis Buy or Sell Advice
When is the right time to buy or sell Novartis AG? Buying financial instruments such as Novartis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Novartis in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Printing and Publishing Thematic Idea Now
Printing and Publishing
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Novartis Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |